Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.10 DKK
-0.50 %
Less than 1K followers
PEG
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
-0.50 %
-15.61 %
-27.80 %
-16.67 %
-47.37 %
-44.44 %
-79.59 %
-79.80 %
-99.62 %
Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.
Read moreMarket cap
122.76M DKK
Turnover
63.8K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Latest research
Latest analysis report
Released: 10.09.2025
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026
The Board of Directors' resolution on the issuance of convertible loans
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
